BMI 18.5 to 35, and body weight ≤150 kg, inclusive.
You may not be if
Evidence of clinically significant disease that may increase the risk to the subject of study participation or interfere with interpretation of results.
Secondary hyperlipidemia.
Subjects who have taken lipid lowering compounds within the past 12 months prior to dosing.
Clareo Health | A Study To Access The Safety And Tolerability Of RN316 (PF-04950615) When Administered To Healthy Adult Subjects
